Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 1:40 AM
Ignite Modification Date: 2025-12-25 @ 11:56 PM
NCT ID: NCT03991494
Description: None
Frequency Threshold: 0
Time Frame: Approximately 30 days after the last dose of pamiparib - up to 6 months
Study: NCT03991494
Study Brief: Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Pamiparib Research Phase (Part 1): participants received a single dose of 60 mg \[14C\]-pamiparib orally Treatment phase (Part 2): participants received 60 mg pamiparib twice daily orally 0 None 0 4 4 4 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Constipation NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Abdominal distension NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Dysgeusia NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (23.0) View
Dyspnoea NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (23.0) View
Fatigue NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (23.0) View
Nausea NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Abdominal discomfort NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Abdominal pain NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Abdominal pain upper NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Amylase increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (23.0) View
Anaemia NON_SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (23.0) View
Arthralgia NON_SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (23.0) View
Blood alkaline phosphatase increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (23.0) View
Depressed level of consciousness NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (23.0) View
Diarrhoea NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Dizziness NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (23.0) View
Dry Mouth NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Flatulence NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (23.0) View
Gamma-glutamyltransferase increased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (23.0) View
Headache NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (23.0) View
Influenza like illness NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (23.0) View
Musculoskeletal pain NON_SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (23.0) View
Oedema peripheral NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (23.0) View
Radiculopathy NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (23.0) View
Sinusitis NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (23.0) View
Tremor NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (23.0) View
Urinary tract infection NON_SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (23.0) View